BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26057469)

  • 1. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
    Luo S; Chen L; Chen X; Xie X
    Oncotarget; 2015 Jun; 6(18):16725-34. PubMed ID: 26057469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis.
    Jiang T; Min W; Li Y; Yue Z; Wu C; Zhou C
    Cancer Med; 2016 Jun; 5(6):1055-65. PubMed ID: 26990668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
    Song Z; Zhang Y
    J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
    Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
    Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
    Jiang Y; Bi Z; Li D; Liu Y
    Zhonghua Yi Xue Za Zhi; 2015 Feb; 95(5):386-91. PubMed ID: 26168678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
    Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V
    Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
    Zhang J; Yu J; Sun X; Meng X
    Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
    Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
    PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
    Zheng MH; Sun HT; Xu JG; Yang G; Huo LM; Zhang P; Tian JH; Yang KH
    Biomed Res Int; 2016; 2016():5807346. PubMed ID: 27006948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole brain radiotherapy plus concurrent chemotherapy in non-small cell lung cancer patients with brain metastases: a meta-analysis.
    Qin H; Pan F; Li J; Zhang X; Liang H; Ruan Z
    PLoS One; 2014; 9(10):e111475. PubMed ID: 25347291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
    BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer.
    Sung S; Lee SW; Kwak YK; Kang JH; Hong SH; Kim YS
    J Neurooncol; 2018 Aug; 139(1):205-213. PubMed ID: 29644484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.
    Shukuya T; Takahashi T; Naito T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Murakami H; Harada H; Mitsuya K; Endo M; Nakasu Y; Takahashi K; Yamamoto N
    Lung Cancer; 2011 Dec; 74(3):457-61. PubMed ID: 21571388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.